Refractory Sudden Sensorineural Hearing Loss
Conditions
Interventions
Treatment group:Ultrasound-Guided Superior Cervical Ganglion Block Combined with Conventional Therapy
Control group:Ultrasound-guided Sham Needling Combined with Conventional Therapy
Sponsors
The First Affiliated Hospital of Air Force Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meeting the diagnostic criteria for sudden sensorineural hearing loss (SSNHL): idiopathic sensorineural hearing loss occurring suddenly within 72 hours, with a hearing decrease of no less than 20 dBHL at at least two adjacent frequencies; 2. Disease duration more than 10 days with no response to initial combined treatment including systemic glucocorticoids (improvement in affected pure tone average (PTA) 60 dBHL; 4. No family history of sensorineural hearing loss; 5. Voluntary participation and signing of informed consent.
Exclusion criteria
Exclusion criteria: 1. Hearing loss with identifiable etiologies, such as Meniere’s disease, acoustic neuroma, traumatic brain injury, history of ototoxic drug use, etc.; 2. Contraindications to superior cervical ganglion block: infection or tumor at the puncture site, severe coagulation disorders, history of local anesthetic allergy, and poorly controlled diabetes mellitus (fasting blood glucose >=10.0 mmol/L); 3. Patients with severe dysfunction of vital organs including the heart, liver, lungs, kidneys, or those with psychiatric disorders; 4. Pregnant or lactating women; 5. Patients with psychiatric disorders or cognitive dysfunction who are unable to fully understand the research scales.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At the end of one treatment course (within two weeks, with at least 8 sessions of SCGB completed), the improvement in pure tone average (PTA) of the affected ear at 0.25–8 kHz (; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean Pure Tone Average (PTA);Overall effective rate;Markedly effective rate;Improvement of tinnitus symptoms; Improvement of vertigo symptoms;Distortion product otoacoustic emission (DPOAE) results;Duration of Horner’s sign and all adverse events; | — |
Countries
China
Contacts
Public ContactGu Nan
The First Affiliated Hospital of Air Force Medical University
Outcome results
None listed